These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1806470)

  • 1. Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination.
    Pocchiari M; Peano S; Conz A; Eshkol A; Maillard F; Brown P; Gibbs CJ; Xi YG; Tenham-Fisher E; Macchi G
    Horm Res; 1991; 35(3-4):161-6. PubMed ID: 1806470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human growth hormone? Inactivation experiments with the 263K strain of scrapie. Rapid communication.
    Pocchiari M; Macchi G; Peano S; Conz A
    Arch Virol; 1988; 98(1-2):131-5. PubMed ID: 3277594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy.
    Brown P; Gajdusek DC; Gibbs CJ; Asher DM
    N Engl J Med; 1985 Sep; 313(12):728-31. PubMed ID: 3929089
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone.
    Gibbs CJ; Joy A; Heffner R; Franko M; Miyazaki M; Asher DM; Parisi JE; Brown PW; Gajdusek DC
    N Engl J Med; 1985 Sep; 313(12):734-8. PubMed ID: 2863752
    [No Abstract]   [Full Text] [Related]  

  • 5. [Creutzfeldt-Jakob disease in 4 children treated with growth hormone].
    Billette de Villemeur T; Gourmelen M; Beauvais P; Rodriguez D; Vaudour G; Deslys JP; Dormont D; Richard P; Richardet JM
    Rev Neurol (Paris); 1992; 148(5):328-34. PubMed ID: 1448646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creutzfeldt-Jakob disease infectivity of growth hormone derived from human pituitary glands.
    Gibbs CJ; Asher DM; Brown PW; Fradkin JE; Gajdusek DC
    N Engl J Med; 1993 Feb; 328(5):358-9. PubMed ID: 8419831
    [No Abstract]   [Full Text] [Related]  

  • 7. Bovine spongiform encephalopathy in cattle mimics ultrastructurally experimental scrapie and Creutzfeldt-Jakob disease in rodents.
    Liberski PP; Yanagihara R; Wells GA; Gajdusek DC
    Neuropatol Pol; 1993; 31(1-2):1-16. PubMed ID: 8208436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy.
    Fisman M
    N Engl J Med; 1986 Apr; 314(15):987-8. PubMed ID: 3515181
    [No Abstract]   [Full Text] [Related]  

  • 9. Contamination of human growth hormone with Creutzfeldt-Jakob disease agent.
    Taylor DM
    Biomed Pharmacother; 1987; 41(5):255. PubMed ID: 3311193
    [No Abstract]   [Full Text] [Related]  

  • 10. Human pituitary growth hormone and Creutzfeldt-Jakob disease.
    Preece M
    Horm Res; 1993; 39(3-4):95-8. PubMed ID: 8262483
    [No Abstract]   [Full Text] [Related]  

  • 11. Inactivation of human immunodeficiency virus during human growth hormone production.
    Dormont D; Vaslin B; Dubeaux D; Boussin F; Maillard F; Deslys JP
    Arch Virol; 1988; 100(1-2):135-8. PubMed ID: 3390001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prions--infectious pathogens causing the spongiform encephalopathies.
    Prusiner SB; Kingsbury DT
    CRC Crit Rev Clin Neurobiol; 1985; 1(3):181-200. PubMed ID: 3915974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone.
    Swerdlow AJ; Higgins CD; Adlard P; Jones ME; Preece MA
    Neurology; 2003 Sep; 61(6):783-91. PubMed ID: 14504321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A patient with Creutzfeldt-Jakob disease following treatment with human growth hormone].
    Roos RA; Wintzen AR; Will RG; Ironside JW; van Duinen SG
    Ned Tijdschr Geneeskd; 1996 Jun; 140(22):1190-3. PubMed ID: 8692356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A statistical model to identify the contaminated lots implicated in iatrogenic transmission of Creutzfeldt-Jakob disease among French human growth hormone recipients.
    Huillard d'Aignaux J; Alpérovitch A; Maccario J
    Am J Epidemiol; 1998 Mar; 147(6):597-604. PubMed ID: 9521187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of transmission of Creutzfeldt-Jakob disease via blood and blood products. The French risk-analysis over the last 15 years.
    Martin M; Trouvin JH
    Transfus Clin Biol; 2013 Sep; 20(4):398-404. PubMed ID: 23910008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and prevention of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease.
    Irani DN; Johnson RT
    Annu Rev Med; 2003; 54():305-19. PubMed ID: 12525677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prion encephalopathies of animals and humans.
    Prusiner SB
    Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prions and orthopedic surgery.
    Doerr HW; Cinatl J; Stürmer M; Rabenau HF
    Infection; 2003 Jun; 31(3):163-71. PubMed ID: 12789474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: a 5-year update.
    Lescoutra-Etchegaray N; Jaffré N; Sumian C; Durand V; Correia E; Mikol J; Luccantoni-Freire S; Culeux A; Deslys JP; Comoy EE
    Transfusion; 2015 Jun; 55(6):1231-41. PubMed ID: 25647476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.